Could an arsenic drink replace IV drips for leukemia patients?
NCT ID NCT06882031
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an oral liquid form of arsenic trioxide (SDK001) in 12 people with acute promyelocytic leukemia (APL). Researchers compared how well the body absorbs the oral drug versus the standard IV version, and whether food or calcium supplements change absorption. The goal was to gather early data on dosing and safety, not to treat the disease directly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- arsenic trioxide (oral solution and intravenous)
- What this could lead to
- If successful, this could lead to a more convenient oral version of arsenic trioxide for APL patients, reducing the need for IV infusions.
- What could go wrong
- This is a very early Phase 1 study with only 12 people, focused on drug absorption, not on curing or controlling the disease. The oral version may not work as well as the IV form.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE PROMYELOCYTIC LEUKEMIA (APL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Hong Kong-Clinical Trial Centre Phase 1 Centre
Hong Kong, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.